CytomX Therapeutics Raises $41M

San Francisco-based CytomX Therapeutics, a developer of antibody therapeutics, said Tuesday that it has raised $41M in an expanded, Series B financing round. The round was led by Canaan Partners, and also included Third Rock Ventures and the Roche Venture Fund. The company said that Canaan's Tim Shannon joins its board. Cytomx is aiming its monoclonal antibodies at oncology, inflammation, and other areas. $30M of the Series B funding was received by the firm back in 2010. More information »